A phase II study of paclitaxel/carboplatin plus bevacizumab/erlotinib in the first line treatment of patients with carcinoma of unknown primary site.
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Erlotinib (Primary) ; Paclitaxel (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 01 Apr 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2008 New trial record.